Contents

Foreword ................................................................. vii
Preface ........................................................................ ix
Acknowledgments ........................................................ xi
Contributors .............................................................. xvii

1 Enzyme Kinetics in Drug Metabolism: Fundamentals and Applications .............................................. 1
   Swati Nagar, Upendra A. Argikar, and Donald J. Tweedie

PART I  FUNDAMENTALS OF ENZYME KINETICS

2 Fundamentals of Enzyme Kinetics .............................................................. 9
   Eleanore Seibert and Timothy S. Tracy

3 Different Enzyme Kinetic Models ......................................................... 23
   Eleanore Seibert and Timothy S. Tracy

4 Reversible Mechanisms of Enzyme Inhibition and Resulting Clinical Significance ..................................................... 37
   Barbara Ring, Steven A. Wrighton, and Michael Mohutsky

5 Irreversible Enzyme Inhibition Kinetics and Drug–Drug Interactions ..................................................... 57
   Michael Mohutsky and Stephen D. Hall

6 Multienzyme Kinetics and Sequential Metabolism ......................................................... 93
   Larry C. Wienkers and Brooke Rock

7 Consideration of the Unbound Drug Concentration in Enzyme Kinetics ..................................................... 119
   Nigel J. Waters, R. Scott Obach, and Li Di

PART II  KINETICS OF DRUG METABOLIZING ENZYMES AND TRANSPORTERS

8 Enzyme Kinetics of Oxidative Metabolism: Cytochromes P450 .......................................................... 149
   Ken Korzekwa

9 Enzyme Kinetics, Inhibition, and Regioselectivity of Aldehyde Oxidase ...................................................... 167
   John T. Barr, Kanika Choughule, and Jeffrey P. Jones

10 Enzyme Kinetics of Conjugating Enzymes: PAPS Sulfotransferase ..................................................... 187
    Margaret O. James

11 Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs) ...................................................... 203
    Jin Zhou and John O. Miners

12 Principles and Experimental Considerations for In Vitro Transporter Interaction Assays ..................................................... 229
    Sid Bhoopathy, Chris Bode, Vatsala Naageshwaran, Erica A. Weiskircher-Hildebrandt, and Ismael J. Hidalgo
PART III MODELING CONSIDERATIONS

13 Rationalizing Underprediction of Drug Clearance from Enzyme and Transporter Kinetic Data: From In Vitro Tools to Mechanistic Modeling ................................................................. 255
   Aleksandra Galetin

14 A Structural Model for the Mass Action Kinetic Analysis of P-gp Mediated Transport Through Confluent Cell Monolayers .............. 289
   Joe Bentz and Harma Ellens

15 Systems Biology Approaches to Enzyme Kinetics: Analyzing Network Models of Drug Metabolism ........................................... 317
   Nnenna A. Finn and Melissa L. Kemp

PART IV VARIABILITY IN KINETICS

16 Variability in Human In Vitro Enzyme Kinetics ......................................................... 337
   Ying-Hong Wang and Christopher R. Gibson

17 Sources of Interindividual Variability ................................................................. 363
   Kenneth E. Thummel and Yvonne S. Lin

PART V CASE STUDIES

18 Case Study 1. Practical Considerations with Experimental Design and Interpretation ...... 419
   John T. Barr, Darcy R. Flora, and Otito F. Iwuchukwu

19 Case Study 2. Practical Analytical Considerations for Conducting In Vitro Enzyme Kinetic Studies ......................................................... 431
   Upendra A. Argikar and Swati Nagar

20 Case Study 3. Application of Basic Enzyme Kinetics to Metabolism Studies: Real-Life Examples ................................................................. 441
   Yongmei Li, Michelle McCabe, Lalitha Podila, Timothy S. Tracy, and Donald J. Tweedie

21 Case Study 4. Predicting the Drug Interaction Potential for Inhibition of CYP2C8 by Montelukast ......................................................... 461
   Ken Korzekwa

22 Case Study 5. Deconvoluting Hyperbilirubinemia: Differentiating Between Hepatotoxicity and Reversible Inhibition of UGT1A1, MRP2, or OATP1B1 in Drug Development ...................... 471
   Ian Templeton, Gary Eichenbaum, Rucha Sane, and Jin Zhou

23 Case Study 6. Transporter Case Studies: In Vitro Solutions for Translatable Outcomes ......................... 485
   Sid Bhoopathy, Chris Bode, Vatsala Naageshwaran, Erica A. Weiskircher-Hildebrandt, and Ismael J. Hidalgo